257 related articles for article (PubMed ID: 26075823)
21. Disruption of a regulatory loop between DUSP1 and p53 contributes to hepatocellular carcinoma development and progression.
Hao PP; Li H; Lee MJ; Wang YP; Kim JH; Yu GR; Lee SY; Leem SH; Jang KY; Kim DG
J Hepatol; 2015 Jun; 62(6):1278-86. PubMed ID: 25617504
[TBL] [Abstract][Full Text] [Related]
22. Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers.
Coutant C; Rouzier R; Qi Y; Lehmann-Che J; Bianchini G; Iwamoto T; Hortobagyi GN; Symmans WF; Uzan S; Andre F; de Thé H; Pusztai L
Clin Cancer Res; 2011 Apr; 17(8):2591-601. PubMed ID: 21248301
[TBL] [Abstract][Full Text] [Related]
23. Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors).
Hirokawa Y; Levitzki A; Lessene G; Baell J; Xiao Y; Zhu H; Maruta H
Cancer Lett; 2007 Jan; 245(1-2):242-51. PubMed ID: 16540233
[TBL] [Abstract][Full Text] [Related]
24. DAPK1-p53 interaction converges necrotic and apoptotic pathways of ischemic neuronal death.
Pei L; Shang Y; Jin H; Wang S; Wei N; Yan H; Wu Y; Yao C; Wang X; Zhu LQ; Lu Y
J Neurosci; 2014 May; 34(19):6546-56. PubMed ID: 24806680
[TBL] [Abstract][Full Text] [Related]
25. Death-Associated Protein Kinase 1 as a Promising Drug Target in Cancer and Alzheimer's Disease.
Chen D; Zhou XZ; Lee TH
Recent Pat Anticancer Drug Discov; 2019; 14(2):144-157. PubMed ID: 30569876
[TBL] [Abstract][Full Text] [Related]
26. Intervention of death-associated protein kinase 1-p53 interaction exerts the therapeutic effects against stroke.
Wang X; Pei L; Yan H; Wang Z; Wei N; Wang S; Yang X; Tian Q; Lu Y
Stroke; 2014 Oct; 45(10):3089-91. PubMed ID: 25139875
[TBL] [Abstract][Full Text] [Related]
27. Prospecting for Breast Cancer Blood Biomarkers: Death-Associated Protein Kinase 1 (DAPK1) as a Potential Candidate.
Arko-Boham B; Owusu BA; Aryee NA; Blay RM; Owusu EDA; Tagoe EA; Adams AR; Gyasi RK; Adu-Aryee NA; Mahmood S
Dis Markers; 2020; 2020():6848703. PubMed ID: 32566040
[TBL] [Abstract][Full Text] [Related]
28. Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes
Kong N; Tao W; Ling X; Wang J; Xiao Y; Shi S; Ji X; Shajii A; Gan ST; Kim NY; Duda DG; Xie T; Farokhzad OC; Shi J
Sci Transl Med; 2019 Dec; 11(523):. PubMed ID: 31852795
[TBL] [Abstract][Full Text] [Related]
29. Protein phosphatase Mg2+/Mn2+ dependent 1F promotes smoking-induced breast cancer by inactivating phosphorylated-p53-induced signals.
Tu SH; Lin YC; Huang CC; Yang PS; Chang HW; Chang CH; Wu CH; Chen LC; Ho YS
Oncotarget; 2016 Nov; 7(47):77516-77531. PubMed ID: 27769050
[TBL] [Abstract][Full Text] [Related]
30. Death-associated protein kinase 1 phosphorylates MDM2 and inhibits its protein stability and function.
Zhang M; Shui X; Zheng X; Lee JE; Mei Y; Li R; Tian Y; Zheng X; Wang Q; Wang L; Chen D; Zhang T; Kim BM; Kim J; Lee TH
Arch Pharm Res; 2023 Dec; 46(11-12):882-896. PubMed ID: 37804415
[TBL] [Abstract][Full Text] [Related]
31. MDM4 is a rational target for treating breast cancers with mutant p53.
Miranda PJ; Buckley D; Raghu D; Pang JB; Takano EA; Vijayakumaran R; Teunisse AF; Posner A; Procter T; Herold MJ; Gamell C; Marine JC; Fox SB; Jochemsen A; Haupt S; Haupt Y
J Pathol; 2017 Apr; 241(5):661-670. PubMed ID: 28097652
[TBL] [Abstract][Full Text] [Related]
32. Mutant p53 and mTOR/PKM2 regulation in cancer cells.
Dando I; Cordani M; Donadelli M
IUBMB Life; 2016 Sep; 68(9):722-6. PubMed ID: 27385486
[TBL] [Abstract][Full Text] [Related]
33. Distinctive role of SIK1 and SIK3 isoforms in aerobic glycolysis and cell growth of breast cancer through the regulation of p53 and mTOR signaling pathways.
Ponnusamy L; Manoharan R
Biochim Biophys Acta Mol Cell Res; 2021 Apr; 1868(5):118975. PubMed ID: 33545220
[TBL] [Abstract][Full Text] [Related]
34. Mutant p53 in breast cancer: potential as a therapeutic target and biomarker.
Duffy MJ; Synnott NC; Crown J
Breast Cancer Res Treat; 2018 Jul; 170(2):213-219. PubMed ID: 29564741
[TBL] [Abstract][Full Text] [Related]
35. Death-Associated Protein Kinase 1 Promotes Alveolar Epithelial Cell Apoptosis and Ventilator-Induced Lung Injury Through P53 Pathway.
Wang Y; Fang X; Yang Y; Chen L; Xiong W; Song L; Li B; Zhou T; Yu Y; Yang X; Shu H; Yuan S; Yao S; Shang Y
Shock; 2022 Jan; 57(1):140-150. PubMed ID: 34265832
[TBL] [Abstract][Full Text] [Related]
36. Enhanced breast cancer progression by mutant p53 is inhibited by the circular RNA circ-Ccnb1.
Fang L; Du WW; Lyu J; Dong J; Zhang C; Yang W; He A; Kwok YSS; Ma J; Wu N; Li F; Awan FM; He C; Yang BL; Peng C; MacKay HJ; Yee AJ; Yang BB
Cell Death Differ; 2018 Dec; 25(12):2195-2208. PubMed ID: 29795334
[TBL] [Abstract][Full Text] [Related]
37. The prognostic significance of DAPK1 in bladder cancer.
Xie JY; Chen PC; Zhang JL; Gao ZS; Neves H; Zhang SD; Wen Q; Chen WD; Kwok HF; Lin Y
PLoS One; 2017; 12(4):e0175290. PubMed ID: 28388658
[TBL] [Abstract][Full Text] [Related]
38. Molecularly targeted therapies for p53-mutant cancers.
Zhao D; Tahaney WM; Mazumdar A; Savage MI; Brown PH
Cell Mol Life Sci; 2017 Nov; 74(22):4171-4187. PubMed ID: 28643165
[TBL] [Abstract][Full Text] [Related]
39. Treatment of primary and metastatic breast and pancreatic tumors upon intravenous delivery of a PRDM14-specific chimeric siRNA/nanocarrier complex.
Taniguchi H; Natori Y; Miyagi Y; Hayashi K; Nagamura F; Kataoka K; Imai K
Int J Cancer; 2021 Aug; 149(3):646-656. PubMed ID: 33783816
[TBL] [Abstract][Full Text] [Related]
40. Mutant p53-associated myosin-X upregulation promotes breast cancer invasion and metastasis.
Arjonen A; Kaukonen R; Mattila E; Rouhi P; Högnäs G; Sihto H; Miller BW; Morton JP; Bucher E; Taimen P; Virtakoivu R; Cao Y; Sansom OJ; Joensuu H; Ivaska J
J Clin Invest; 2014 Mar; 124(3):1069-82. PubMed ID: 24487586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
